MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.4 CHF | +2.56% |
|
+1.19% | -1.16% |
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.4
CHF
Average target price
9.35
CHF
Spread / Average Target
+175.00%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.16% | 125M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- MOLN Stock
- Funds and ETFs Molecular Partners AG
